These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20967130)

  • 1. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.
    Goñi F; Prelli F; Ji Y; Scholtzova H; Yang J; Sun Y; Liang FX; Kascsak R; Kascsak R; Mehta P; Wisniewski T
    PLoS One; 2010 Oct; 5(10):e13391. PubMed ID: 20967130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.
    Goñi F; Herline K; Peyser D; Wong K; Ji Y; Sun Y; Mehta P; Wisniewski T
    J Neuroinflammation; 2013 Dec; 10():150. PubMed ID: 24330773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
    Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
    BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Alzheimer's disease.
    Wisniewski T; Goñi F
    Biochem Pharmacol; 2014 Apr; 88(4):499-507. PubMed ID: 24412277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination as a therapeutic approach to Alzheimer's disease.
    Wisniewski T; Boutajangout A
    Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice.
    Zhang Y; Zou J; Yang J; Yao Z
    Curr Alzheimer Res; 2015; 12(4):384-97. PubMed ID: 25817256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.
    Magga J; Puli L; Pihlaja R; Kanninen K; Neulamaa S; Malm T; Härtig W; Grosche J; Goldsteins G; Tanila H; Koistinaho J; Koistinaho M
    J Neuroinflammation; 2010 Dec; 7():90. PubMed ID: 21138577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligomeric Forms of Human Amyloid-Beta(1-42) Inhibit Antigen Presentation.
    Gericke C; Mallone A; Engelhardt B; Nitsch RM; Ferretti MT
    Front Immunol; 2020; 11():1029. PubMed ID: 32582162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.
    Liu S; Breitbart A; Sun Y; Mehta PD; Boutajangout A; Scholtzova H; Wisniewski T
    J Neurochem; 2014 Feb; 128(4):577-91. PubMed ID: 24117759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.
    Button EB; Boyce GK; Wilkinson A; Stukas S; Hayat A; Fan J; Wadsworth BJ; Robert J; Martens KM; Wellington CL
    Alzheimers Res Ther; 2019 May; 11(1):44. PubMed ID: 31084613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine models of Alzheimer's disease and their use in developing immunotherapies.
    Wisniewski T; Sigurdsson EM
    Biochim Biophys Acta; 2010 Oct; 1802(10):847-59. PubMed ID: 20471477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.
    Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH
    PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.